Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below 200 Day Moving Average – Should You Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.35 and traded as low as $1.1250. Spero Therapeutics shares last traded at $1.15, with a volume of 1,373,021 shares traded.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce”.

Spero Therapeutics Stock Performance

The stock has a market cap of $72.95 million, a price-to-earnings ratio of 5.25 and a beta of 1.55. The business has a 50-day simple moving average of $2.09 and a two-hundred day simple moving average of $2.34.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. Spero Therapeutics had a net margin of 24.90% and a return on equity of 35.58%. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.26 million.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SPRO. XTX Topco Ltd bought a new position in shares of Spero Therapeutics in the 2nd quarter valued at about $100,000. Invesco Ltd. bought a new stake in Spero Therapeutics during the second quarter worth about $43,000. Vanguard Group Inc. raised its holdings in Spero Therapeutics by 2.0% during the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock worth $3,741,000 after acquiring an additional 39,474 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Spero Therapeutics during the third quarter valued at approximately $55,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Spero Therapeutics during the third quarter valued at approximately $283,000. 25.60% of the stock is owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.